Plug-and-play assembly of biodegradable ionizable lipids for potent mRNA delivery and gene editing in vivo
Abstract
mRNA-based gene editing therapeutics offer the potential to permanently cure diseases but are hindered by suboptimal delivery platforms. Here, we devise a robust combinatorial chemistry for the plug-and-play assembly of structurally diverse biodegradable ionizable lipids from amines/thiols and dialkyl maleates. After screening 500 ionizable lipids, we obtained structure−activity relationships essential for effective in vitro mRNA delivery with the help of machine learning. Furthermore, we identified a lead ionizable lipid candidate that produced potent lipid nanoparticles for the delivery of various gene editing tools in wild-type and genetically modified mice compared to literature and industry benchmark lipid nanoparticles. Mechanistically, our lipid nanoparticles show favorable physicochemical properties, which could synergistically contribute to the superior delivery performance. This study highlights the utility of this synthetic method as well as the generality of this platform for potent in vivo gene editing.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (15)
Xuexiang Han
Ying Xu
Adele S. Ricciardi
Department of Bioengineering
Junchao Xu
Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Yan Xiang
Department of Biomedical Engineering, Duke University
Rohan Palanki
Vivek Chowdhary
Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania
Lulu Xue
Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Ningqiang Gong
Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Mohamad-Gabriel Alameh
William H. Peranteau
Division of Pediatric General, Thoracic, and Fetal Surgery, The Center for Fetal Research, Children’s Hospital of Philadelphia
James M. Wilson
Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania
Daniel Reker
Department of Biomedical Engineering, Duke University
Drew Weissman
Michael J. Mitchell